McCord M W, Buatti J M, Fennell E M, Mendenhall W M, Marcus R B, Rhoton A L, Grant M B, Friedman W A
Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, USA.
Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):437-44. doi: 10.1016/s0360-3016(97)00335-0.
To review outcome and treatment sequelae in patients treated with external beam radiotherapy for pituitary adenomas.
One hundred forty-one patients with pituitary adenomas received radiotherapy at the University of Florida and had 2-year minimum potential follow-up. One hundred twenty-one had newly diagnosed adenomas, and 20 had recurrent tumors. Newly diagnosed tumors were treated with surgery and radiotherapy (n = 98) or radiotherapy alone (n = 23). Patients with recurrent tumors received salvage treatment with surgery and radiotherapy (n = 10) or radiotherapy alone (n = 10). The impact of age, sex, presenting symptoms, tumor extent, surgery type, degree of resection, hormonal activity, primary or salvage therapy, and radiotherapy dose on tumor control was analyzed. Tumor control is defined by the absence of radiographic progression and stable or decreased hormone level (in hormonally active tumors) after treatment. Effect of therapy on vision, hormonal function, neurocognitive function, life satisfaction, and affective symptoms were examined. A Likert categorical scale survey was used for assessment of neurocognitive, life satisfaction, and affective symptom status. Survey results from the radiotherapy patients were compared with a control group treated with transsphenoidal surgery alone. Multivariate analysis used the forward step-wise sequence of chi squares for the log rank test.
At 10 years, tumor control for the surgery and radiotherapy group (S + RT) was 95% and not statistically different (p = 0.58) than for patients treated with radiotherapy alone (RT) (90%). Patients with prolactin- and ACTH-secreting tumors had significantly worse tumor control, as did patients treated for recurrent tumors. Multivariate analysis for tumor control revealed that only young age was predictive of worse outcome (p = 0.0354). Visual function was either unaffected or improved in most patients, although four patients developed visual loss due to treatment. Hormonal function was affected adversely in 46 of the 93 patients for whom detailed hormonal information was available. Neurocognitive function evaluation revealed that patients in the S + RT group were more likely (p = 0.005) to report difficulty with memory than those in the RT-alone or S-alone groups. No significant difference in life satisfaction or affective symptoms was evident.
Pituitary adenomas are well controlled by external beam radiotherapy, either alone or in combination with surgery. Visual symptoms often improve after treatment. Hormonal sequelae require medical intervention in many patients. Neurocognitive sequelae may be different among treatment groups.
回顾接受垂体腺瘤外照射放疗患者的治疗结果及治疗后遗症。
141例垂体腺瘤患者在佛罗里达大学接受放疗,且至少有2年的潜在随访期。其中121例为新诊断的腺瘤,20例为复发性肿瘤。新诊断的肿瘤患者接受手术加放疗(n = 98)或单纯放疗(n = 23)。复发性肿瘤患者接受手术加放疗的挽救性治疗(n = 10)或单纯放疗(n = 10)。分析年龄、性别、首发症状、肿瘤范围、手术类型、切除程度、激素活性、初次或挽救性治疗以及放疗剂量对肿瘤控制的影响。肿瘤控制定义为治疗后影像学无进展且激素水平稳定或下降(对于有激素活性的肿瘤)。检查治疗对视力、激素功能、神经认知功能、生活满意度和情感症状的影响。采用李克特分类量表调查评估神经认知、生活满意度和情感症状状态。将放疗患者的调查结果与单纯经蝶窦手术治疗的对照组进行比较。多变量分析使用卡方的向前逐步序列进行对数秩检验。
10年后,手术加放疗组(S + RT)的肿瘤控制率为95%,与单纯放疗组(RT)(90%)相比无统计学差异(p = 0.58)。分泌催乳素和促肾上腺皮质激素的肿瘤患者以及复发性肿瘤患者的肿瘤控制情况明显较差。肿瘤控制的多变量分析显示,只有年轻患者的预后较差(p = 0.0354)。大多数患者的视觉功能未受影响或有所改善,尽管有4例患者因治疗出现视力丧失。在可获得详细激素信息的93例患者中,46例患者的激素功能受到不利影响。神经认知功能评估显示,S + RT组患者比单纯放疗组或单纯手术组患者更有可能(p = 0.005)报告记忆困难。生活满意度或情感症状方面无明显差异。
垂体腺瘤通过外照射放疗单独或联合手术能得到良好控制。治疗后视觉症状通常会改善。许多患者的激素后遗症需要医学干预。不同治疗组的神经认知后遗症可能有所不同。